Gib hier deine Überschrift ein


The Life Science industry is undergoing rapid changes that require strategic buying and selling decisions.

At Sinfonie, we have accompanied several companies on their transaction journey. This allows us to share our expertise on both – the sell and the buy side.

We believe that a transaction process should be tailored to the individual needs of your company.

Rationales to sell

There are a variety of reasons why a company might decide to sell.

Generate Liquidity
Owners, particularly of private illiquid businesses, often have a significant part of their net worth tied up in the business. A sale – either partial or full – is a way to generate cash for the owners.
No clear succession or internal disputes
Owners who are getting older without a clear management succession plan may look to sell, as may owners of a closely held businesses who are in conflict.
Strategic sell rationale
The business might decide that it’s more likely to sustain or grow its competitive advantage if combined with a strategic acquirer. For example, joining forces with a competitor, customer or supplier could help scale, create synergies or open new markets.
Strategic divestment
Larger corporations may decide to divest partial businesses because their corporate strategy changed or for improving key financial or performance parameters.
The business might be distressed, facing liquidity problems that it cannot resolve on its own through a financial or operational restructuring.

Our services to the sell side

The sell-side process might begin when an unsolicited buyer approaches the seller or when an owner independently arrives at the decision to sell. Ultimately, the seller has four ways it can organize the deal process.


Broad auction


Limited auction


Targeted auction


Exclusive negotiation

As soon as we have understood the reason and rationale of the selling party, we strategically position assets and companies for the transactions with upfront work before making the first outreach call.

Rationales to buy

There are also a variety of reasons why a company might decide to buy.

By combining business activities, overall performance efficiency tends to increase and across-the-board costs tend to drop, due to the fact that each company leverages off of the other company's strengths.
By buying out one of its suppliers or distributors, a business can eliminate an entire tier of costs. Specifically, buying out a supplier, which is known as a vertical merger, lets a company save on the margins the supplier was previously adding to its costs. And by buying out a distributor, a company often gains the ability to ship out products at a lower cost.
Increase Supply-Chain Pricing Power
Merger can give the acquiring company an opportunity to grow market share without doing significant heavy lifting.
Eliminate Competition
Many M&A deals allow the acquirer to eliminate future competition and gain a larger market share. On the downside, a large premium is usually required to convince the target company's shareholders to accept the offer.

Our services to the buy side

When we have accepted a buy side mandate

  • we start with a corporate or portfolio strategy initiative to ensure sufficient thought has been given to a client’s growth strategy. 
  • we continue with a global asset screen to identify the most promising potential licensing and acquisition targets. 
  • we execute the transaction from outreach through deal closure.
Target identification and engagement
Preliminary due diligence, valuation, and indication of interest
Further due diligence and letter of intent
Final due diligence, negotiations, drafting of the definitive purchase agreement, and completion of the transaction

Recent deal example in cooperation with Alira Health

2020 | Advisory of AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), in their acquisition of MolMed SpA, an Italian biotechnology company focused on research, development, production, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases | € 240 million